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ABSTRACT
Background: Discoid lupus erythematosus (DLE) is a common canine autoimmune skin disease, in which systemic 
manifestations are absent. Skin Lesions are usually present on the nasal planum, and characterised by erythema, depig-
mentation, erosion, ulceration, and crusting. The diagnosis is based on histopathological results, which should demonstrate 
lymphoplasmacytic lichenoid-interface dermatitis. Human intravenous immunoglobulin (hIVIg) has been used in veterinary 
medicine to treat cutaneous diseases including erythema multiforme, PF, and severe adverse cutaneous drug reactions. In 
human medicine, it has been effective to treat DLE. This report firstly describes the clinical response to hIVIg in a dog 
with DLE resistant to common immunosuppressive drugs. 
Case: A 5-year-old, intact female Shih Tzu presented with a 1-month history of slowly progressive black crusting on the 
nasal planum, chin, and claw. Based on the results of a dermatologic examination, superficial pyoderma was diagnosed. 
The skin lesions did not improve during and after anti-infective treatment. After removing the crusts, a skin biopsy was 
obtained from the muzzle. Histopathology of lesional skin biopsy specimens revealed lymphoplasmacytic interface dermatitis 
at the dermoepidermal junction. Microscopic examination also revealed vacuolar changes and pigmentary incontinence 
of the basal layer as a lichenoid tissue reaction. No mites or fungi were detected on the skin section. The absence of acan-
tholytic cells excluded pemphigus foliaceus, which is also characterised by the lesions of the nasal planum. Based on the 
distribution of the lesions, histopathology and exclusion of other dermatoses, the dog was diagnosed with DLE. The skin 
lesions temporarily improved after treatment with prednisolone (2 mg/kg PO q12h). However, after tapering the dose of 
prednisolone, new black crusts developed on the nasal planum and claw. Although the dog was successively treated with 
other immunosuppressive drugs, including azathioprine, cyclosporin with dexamethasone, and mycophenolate mofetil, 
black crusts still remained. Due to the low efficacy of these immunosuppressive drugs, hIVIg was administered at 0.5 g/kg 
once daily for 4 days, for a total dose of 2 g/kg. During hIVIg administration, the crusted lesions gradually improved. After 
the hIVIg administration, the dog was treated with prednisolone (1 mg/kg PO q12h). The lesions were almost in complete 
remission at 21 days after an additional application of prednisolone. The skin lesions did not recur, and the treatment was 
eventually discontinued after 6 weeks of additional prednisolone application. 
Discussion: The standard treatment of canine DLE includes glucocorticoids, and second-line immunosuppressive drugs, 
such as azathioprine and cyclosporine, are usually added in cases resistant to steroids. This case suggests that hIVIg may be 
beneficial as an adjunctive treatment option for canine DLE, especially when the application of standard immunosuppres-
sive drugs is limited due to adverse effects or low efficacy. There is evidence from several studies that the steroid-sparing 
effect of hIVIg is significant in human patients. In the current case, the effective dose of prednisolone was reduced to 2 
mg/kg/day after hIVIg administration, and prednisolone therapy was finally discontinued completely. The hIVIg appears 
to lower the daily steroid dose requirement in this dog.
Keywords: autoimmune skin disease, discoid lupus erythematosus, canine dermatology, immunosuppressive drug, human 
intravenous immunoglobulin.
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INTRODUCTION
Discoid lupus erythematosus (DLE) is a com-
mon canine autoimmune skin disease, with skin lesions 
usually characterised by erythema, depigmentation, 
erosion, ulceration, and crusting of the nasal planum 
and surrounding skin [17]. Glucocorticoids are the 
first-line drugs for the treatment of DLE [14]. It is 
important to use alternative or adjunctive immunosu-
ppressive therapy for clinical response enhancement 
and reduction of the adverse effects of steroids [22]. 
In human medicine, human intravenous immu-
noglobulin (hIVIg) is used in autoimmune and inflam-
matory diseases. Although data on the efficacy of hI-
VIg in human DLE are limited, it has been successfully 
used to treat human DLE [20]. Furthermore, hIVIg is 
considered as an adjunctive therapy in the management 
of dogs resistant to standard immunosuppressive pro-
tocols [22]. The hIVIg has been used in veterinary me-
dicine to treat immune-mediated haemolytic anaemia, 
thrombocytopenia, and cutaneous diseases [1,4,7,18]. 
In 2006, Rahilly et al. [15] described the successful use 
of hIVIg to treat a dog with severe pemphigus foliaceus 
(PF), the most common canine immune-mediated skin 
disease. However, there are no reports on the use of 
hIVIg in canine DLE. This report firstly describes the 
clinical response to hIVIg in a dog with DLE resistant 
to common immunosuppressive drugs.
CASE 
A 5-year-old, intact female Shih Tzu presented 
with a 1-month history of slowly progressive black 
crusting on the nasal planum, chin, and claw, as well 
as a 3-year history of pruritus on the face, ventral 
abdomen, four paws, and both ear pinnae (Figure 1). 
No other notable findings were observed on physical 
examination. Cytological examination of the lesions 
revealed bacterial infection, but no acantholytic cells. 
Scraping, trichogram, and Wood’s lamp examination 
were unremarkable.
Based on the results of a dermatologic exa-
mination, superficial pyoderma was diagnosed. The 
initial differential diagnoses included deep pyoderma, 
autoimmune disease, atopic dermatitis, cutaneous ad-
verse food reaction, demodicosis, and dermatophytosis. 
The dog was treated for 18 days with amoxicillin-cla-
vulanate1 [25 mg/kg PO q12h] and 2% chlorhexidine 
and miconazole shampoos2 [twice a week; Malaseb-F]. 
Escherichia coli was isolated from a swab of the skin 
lesions, and due to a lack of improvement, the dog was 
treated for 6 days with trimethoprim/sulfamethoxazole3 
[30 mg/kg PO q12h], in accordance with the results 
of an antimicrobial susceptibility test. For the next 6 
days, ivermectin4 [300 mcg/kg PO q24h; Ivomec] and 
itraconazole5 [10 mg/kg PO q24h; Sponazol Tab.] were 
added to differentiate demodicosis and dermatophyto-
sis. However, the skin lesions did not improve during 
and after anti-infective treatment. Results of fungal 
cultures were also negative. 
After removing the crusts, a skin biopsy was 
obtained from the muzzle. Histopathology of lesional 
skin biopsy specimens revealed mild epidermal hyper-
plasia and interface dermatitis at the dermoepidermal 
junction (Figure 2). The interface dermatitis was com-
posed of lymphocytes and plasma cells. Microscopic 
examination also revealed vacuolar changes and pig-
mentary incontinence of the basal layer as a lichenoid 
tissue reaction. Crusts and inflammatory cells were 
seen on the epidermis. The crusts were mainly com-
posed of neutrophils. No mites or fungi were detected 
on the skin section. The absence of acantholytic cells 
excluded PF, which is also characterised by the lesions 
of the nasal planum. Clinical features, histopathologic 
findings, and exclusion of other dermatoses supported 
the diagnosis of DLE. 
Given the diagnosis of DLE, the dog was 
treated for 1 week with prednisolone6 [2 mg/kg PO 
q12h; Solondo Tab.] and topical hydrocortisone cre-
am7 [twice per day; Hydrocortisone Ointment]. This 
treatment resulted in a temporary improvement in the 
skin lesion. The prednisolone dose was reduced to 
1.5 mg/kg q12h, and the skin lesions again worsened. 
Azathioprine8 [2 mg/kg PO q24h, Immuthera Tab.] 
was added in the last week of prednisolone treatment 
due to the lack of a clinical response to the steroid; 
prednisolone was administered for a total of 1 month 
and stopped after tapering. Because new black crusts 
developed on the nasal planum and claw, cyclosporin9 
[8 mg/kg PO q24h for 1 month, Cipol-N Soft Cap.] was 
initiated concurrently with dexamethasone6 [0.3 mg/kg 
PO q12h for 1 week, followed by 0.3 mg/kg PO q24h 
for 3 weeks; Dexamethasone Tab.]. The skin lesions 
were not improved after the successive prescriptions 
of azathioprine and cyclosporin with dexamethasone. 
Subsequently, the dog was treated for 1 month with 
mycophenolate mofetil10 [20 mg/kg PO q12h, Cellcept 
Cap.]; however, the skin lesions still did not improve.
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Figure 1. Comparison of the skin lesions, characterised by black crusts on the nasal planum, chin, and claw, between the first visit (A, C, E) and after 
hIVIg human intravenous immunoglobulin administration and additional prednisolone application (B, D, F).  
Due to the insufficient clinical response after 
3 months of immunosuppressive therapy, hIVIg11 (Liv 
gamma Inj.) was administered [0.5 g/kg once daily for 
4 days of hospitalisation, for a total dose of 2 g/kg]. 
After the hIVIg administration, the dog was treated 
with prednisolone (1 mg/kg PO q12h). Three weeks 
later, the black crust on the nasal planum was almost 
in complete remission (Figure 1). The lesions on the 
chin and claw were markedly decreased in severity, but 
some crust remained. The skin lesions did not recur, 
and the treatment was eventually discontinued after 6 
weeks of additional prednisolone application. 
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DISCUSSION
Discoid lupus erythematosus (DLE) is a rela-
tively benign lupus erythematosus, in which systemic 
manifestations are absent [17]. Recently, DLE has 
been classified as the most common form of cutaneous 
lupus erythematosus. Lesions are usually present on the 
nasal planum, and also develop in the ear pinnae and 
periocular region [2]. The diagnosis of DLE is based 
on histopathological results, which should demonstrate 
lymphoplasmacytic lichenoid-interface dermatitis 
[2]. Additionally, direct immunofluorescence and 
immunohistochemistry reveal IgG and IgM deposits 
at the dermoepidermal junction in most cases [2]. In 
the current case, no attempt was made to confirm the 
diagnosis of DLE by direct immunofluorescence or 
immunohistochemistry. However, with reference to 
other DLE studies, the diagnosis was made based on 
the clinical appearance, histopathologic findings, and 
the exclusion of other dermatoses [2,12]. 
The standard treatment of canine DLE includes 
oral and/or topical glucocorticoids [14]. In cases resis-
tant to steroids, second-line immunosuppressive drugs, 
such as azathioprine and cyclosporine, are usually 
added [14,22]. Combined tetracycline-niacinamide, 
topical 0.1% tacrolimus, and hydroxychloroquine can 
also be used as initial treatments [13,19,23]. In general, 
the prognosis of canine DLE is good, with appropriate 
treatment. However, relapses are common after medi-
cations are tapered [2]. 
In cases of human DLE refractory to first-line 
therapy, hIVIg has been employed [20]. The hIVIg 
is a blood product containing primarily IgG, derived 
from the plasma of 1,000 to 60,000 human donors 
[8]. The hIVIg has been used in veterinary medicine 
to treat immune-mediated disorders, such as immune-
-mediated haemolytic anaemia, immune-mediated 
thrombocytopenia, myasthenia gravis, sudden acquired 
retinal degeneration, and cutaneous diseases [1,4,7,18]. 
Especially among dogs with cutaneous diseases, hIVIg 
is used in erythema multiforme, PF, and severe adverse 
cutaneous drug reactions [5,15,21]. 
Nasal depigmentation, erythema, erosion, ul-
ceration, crusts, and haemorrhage are characteristic in 
canine DLE [17]. The main skin lesions in the current 
case were black crusts on the nasal planum, which were 
very similar to those described in canine DLE. Howe-
ver, the other lesions showed some differences, inclu-
ding an unusual distribution (e.g. the chin and claw). 
Although hIVIg is considered as an option 
for human patients with DLE refractory to standard 
therapies, many clinicians are unsure of the role of 
hIVIg in DLE [20]. However, various actions of 
hIVIg have been proposed; the most well described 
actions comprise complement inhibition, Fc receptor 
saturation, pathogenic autoantibody catabolism, and 
the regulation of cytokine release [8]. In the current 
case, no quantitative tests were performed to confirm 
the therapeutic mechanism of DLE. 
The hIVIg appears to lower the daily steroid 
dose requirement. There is evidence from several 
studies that the steroid-sparing effect of hIVIg is signi-
ficant in human patients [3,10,24]. In the current case, 
the effective dose of prednisolone was reduced to 2 mg/
Figure 2. Histopathologic features of the skin biopsy obtained from the muzzle. Mild hyperplasia is observed in the epidermis (arrows). Inflammatory 
cells, composed of lymphocytes and plasma cells, infiltrated the dermoepidermal junction (circles). Note the vacuolar changes in the basal layer (arrow 
heads) [H&E; A: 40x, B: 400x]. 
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kg/day after hIVIg administration, and prednisolone 
therapy was finally discontinued completely. 
There is a risk of an acute hypersensitivity 
reaction to hIVIg administration in dogs due to the 
infusion of human-derived foreign proteins [1]. Other 
adverse effects reported in human medicine include 
thromboembolism, renal insufficiency, hypotension, 
and aseptic meningitis [6,9,11,16]. In the current case, 
no adverse effects were observed during and after 
hIVIg administration. 
In conclusion, this report was the first to 
describe the clinical response to hIVIg in a dog with 
DLE. The hIVIg may be considered as an adjunctive 
treatment option for canine DLE, especially when the 
application of standard immunosuppressive drugs is 
limited due to adverse effects or low efficacy.
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